SARS-CoV-2疫苗接种与绝经前后女性月经紊乱及出血就医关联的全国性登记队列研究
该全国性登记队列研究纳入2 946 448名12-74岁瑞典女性,评估SARS-CoV-2疫苗接种后月经紊乱或出血相关就医风险。绝经后女性第三剂接种后1-7天出血风险比1.28(95%CI 1.01-1.62),8-90天风险比1.25(95%CI 1.04-1.50);绝经前女性关联经协变量调整后几乎完全消失。结论认为证据不支持疫苗接种与月经或出血相关就医存在实质性因果关联。
要点
- 绝经后女性第三剂接种后1-7天出血就医风险比1.28(95%CI 1.01-1.62)。
- 绝经后女性第三剂接种后8-90天出血就医风险比1.25(95%CI 1.04-1.50)。
- 绝经前女性月经紊乱或出血关联经协变量调整后几乎完全消失。
核心结论
- 观察到的SARS-CoV-2疫苗接种与绝经后出血就医关联微弱且不一致,不支持实质性因果关联。
- 绝经前女性月经紊乱或出血与疫苗接种的关联证据更少,调整协变量后几乎消失。
研究设计与样本
- 全国性登记队列研究,覆盖2020年12月27日至2022年2月28日瑞典所有住院和专科门诊,并纳入覆盖40%女性人口的初级保健子集。
- 纳入2 946 448名12-74岁瑞典女性,排除孕妇、养老院居住者及2015年1月1日至2020年12月26日有月经或出血障碍、乳腺癌、女性生殖器官癌或子宫切除术史者。
- 暴露为SARS-CoV-2疫苗接种(BNT162b2、mRNA-1273或ChAdOx1 nCoV-19),按剂次(未接种及第一、二、三剂)和两个时间窗(1-7天为对照期,8-90天)分析。
主要发现
- 2 580 007名(87.6%)女性至少接种一剂SARS-CoV-2疫苗,其中1 652 472名(64.0%)接种三剂。
- 绝经后女性第三剂接种后1-7天出血就医风险比1.28(95%CI 1.01-1.62),8-90天风险比1.25(95%CI 1.04-1.50)。
- 协变量调整对结果影响 modest;第三剂后8-90天BNT162b2和mRNA-1273与绝经后出血风险增加23-33%相关,ChAdOx1 nCoV-19关联较不明确。
- 绝经前女性月经紊乱或出血的粗分析弱关联经协变量调整后几乎完全消失。
关键数值与推荐
- 风险窗口为接种后1-7天(对照期)和8-90天,按疫苗产品和剂次分层分析。
临床怎么用
- 全科医生可告知绝经后女性第三剂SARS-CoV-2疫苗接种后出血就医风险轻微升高但证据不一致,不构成因果依据。
- 对绝经前女性月经紊乱或出血主诉,不应归因于SARS-CoV-2疫苗接种,应按常规路径评估。
- 绝经后出血患者仍需按常规进行妇科评估,疫苗接种史不改变临床处理原则。
局限性
- 观察性登记研究设计不能确立因果关系。
- 初级保健数据仅覆盖40%瑞典女性人口。
- 排除有月经或出血障碍等病史者可能限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the risks of any menstrual disturbance and bleeding following SARS-CoV-2 vaccination in women who are premenopausal or postmenopausal. DESIGN: A nationwide, register based cohort study. SETTING: All inpatient and specialised outpatient care in Sweden from 27 December 2020 to 28 February 2022. A subset covering primary care for 40% of the Swedish female population was also included. PARTICIPANTS: 2 946 448 Swedish women aged 12-74 years were included. Pregnant women, women living in nursing homes, and women with history of any menstruation or bleeding disorders, breast cancer, cancer of female genital organs, or who underwent a hysterectomy between 1 January 2015 and 26 December 2020 were excluded. INTERVENTIONS: SARS-CoV-2 vaccination, by vaccine product (BNT162b2, mRNA-1273, or ChAdOx1 nCoV-19 (AZD1222)) and dose (unvaccinated and first, second, and third dose) over two time windows (one to seven days, considered the control period, and 8-90 days). MAIN OUTCOME MEASURES: Healthcare contact (admission to hospital or visit) for menstrual disturbance or bleeding before or after menopause (diagnosed with the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes N91, N92, N93, N95). RESULTS: 2 580 007 (87.6%) of 2 946 448 women received at least one SARS-CoV-2 vaccination and 1 652 472 (64.0%) 2 580 007 of vaccinated women received three doses before the end of follow-up. The highest risks for bleeding in women who were postmenopausal were observed after the third dose, in the one to seven days risk window (hazard ratio 1.28 (95% confidence interval 1.01 to 1.62)) and in the 8-90 days risk window (1.25 (1.04 to 1.50)). The impact of adjustment for covariates was modest. Risk of postmenopausal bleeding suggested a 23-33% increased risk after 8-90 days with BNT162b2 and mRNA-1273 after the third dose, but the association with ChAdOx1 nCoV-19 was less clear. For menstrual disturbance or bleeding in women who were premenopausal, adjustment for covariates almost completely removed the weak associations noted in the crude analyses. CONCLUSIONS: Weak and inconsistent associations were observed between SARS-CoV-2 vaccination and healthcare contacts for bleeding in women who are postmenopausal, and even less evidence was recorded of an association for menstrual disturbance or bleeding in women who were premenopausal. These findings do not provide substantial support for a causal association between SARS-CoV-2 vaccination and healthcare contacts related to menstrual or bleeding disorders.
引用
- Ljung R, Xu Y, Sundström A, et al. Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study. BMJ. 2023. PMID: 37137493. doi:10.1136/bmj-2023-074778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。